Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance

Globe and Mail

3 days ago

Sonendo, Inc. ('Sonendo' or the 'Company'), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance.
Select Second Quarter Financial Results
Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team;
Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period;
Reported a $3.6 million reduction in loss from continuing operations compared to the prior period, to $3.9 million for the second quarter of 2025;
Drove a 47% year-over-year improvement in Adjusted EBITDA loss to $3.0 million for the second quarter of 2025, driven by focused operational efficiencies;
Significantly reduced free cash flow burn to $2.6 million, a 61% reduction compared to the prior year period.
'We are pleased by the continued progress we have made in generating increasing operating leverage in the business, as demonstrated in our second quarter 2025 financial and operational results,' said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'In particular, we are selling consoles much more efficiently and with a focus on driving higher procedure instrument utilization. We are also focusing the commercial team's efforts on being more responsive to the clinical needs of our customers and their patients. We recently improved the liquidity profile of the Company in a meaningful way, and we remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term and profitable growth.'
As of June 30, 2025, the Company's cash, cash equivalents and short-term investments totaled $9.3 million, and there was $14.2 million of principal outstanding under the Company's credit facility.
Financial Guidance
The Company is reaffirming the 2025 financial guidance it previously provided, which reflects management's latest expectations and is provided below.
(1)
See additional information included in the Company's Form 8-K filed with the Securities and Exchange Commission on November 12, 2024 for additional information about the Company's use of these non-GAAP financial measures.
About Sonendo
Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices.
For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.
Forward-Looking Statements
This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's expectations regarding 2025 financial performance, including (among other things) revenue, gross margin, adjusted EBITDA and free cash flow; and the Company's ability to achieve robust, long-term and profitable growth. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.